Shuttle Pharmaceuticals Holdings heads into today's earnings with one of the most contradictory lending setups in its recent history — borrow costs at extreme levels, yet short sellers rapidly covering.
The cost-to-borrow tells the most striking part of the story. At 156% APR, it remains deeply elevated — more than 57% above where it stood a month ago — signalling that demand to borrow the stock is intense. Yet short interest has collapsed. It fell nearly 82% over the past week, from roughly 977,000 shares short on May 4 to just 143,000 on May 13. Measured against the free float, short interest now runs at around 8.9% — but that figure has been on a steep downward trajectory as bears rapidly covered their positions into the print. With availability at around 118% of current short interest, the lending pool is not yet critically tight, but the cost to borrow at triple-digit rates reflects how painful holding a short position in this stock has become.
The short score underscores how quickly the tide has turned. The ORTEX short score peaked above 81 on May 4, marking the most concentrated bearish signal of the recent period. It has since tumbled to 61, tracking the rapid unwind of short positions almost point for point. That retreat does not make the stock uncontested ground — a score above 60 still indicates meaningful short-side conviction — but the direction of travel is unambiguously one of shorts exiting, not piling in.
Peers offer little counterweight. Close correlated names — CRVS, BRTX, and ATOS — have each fallen between 5% and 24% on the week, suggesting sector-level pressure rather than company-specific optimism driving any bids. SHPH itself is down roughly 9% over the same period, closing at $0.64, with a micro-cap market capitalisation around $3.5 million. No analyst coverage is on record, and insider trading data is stale, leaving the positioning signals as the primary lens through which to read the setup.
The earnings release will test whether the short-covering of the past ten days reflected genuine reassessment — or simply the mechanics of an expensive borrow forcing traders to close, regardless of their view on the underlying science.
See the live data behind this article on ORTEX.
Open SHPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
